Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
AU-rich element RNA-binding protein 1 (AUF1), also known as Heterogeneous nuclear ribonucleoprotein D (hnRNP D), is a critical regulator of post-transcriptional gene expression [UniProt: Q14103]. It functions by binding to AU-rich elements (AREs) located in the 3' untranslated regions (UTRs) of various mRNAs, including those encoding cytokines, oncoproteins, and cell cycle regulators [NCBI Gene: 3184]. AUF1 exists as four isoforms (p37, p40, p42, and p45) that are generated through alternative splicing; these isoforms can either promote the rapid degradation of target mRNAs by recruiting the exosome or stabilize them, depending on the cellular context and the specific isoform involved [PMID: 11500481]. In cancer, AUF1 is frequently overexpressed and contributes to malignancy by stabilizing oncogenic transcripts such as c-Myc and Cyclin D1, while in inflammatory contexts, it regulates the half-life of pro-inflammatory cytokine mRNAs like TNF-alpha and IL-6 [PMID: 23533556]. Beyond mRNA turnover, AUF1 is also involved in telomere maintenance by binding to telomeric repeat sequences and interacting with telomerase [UniProt: Q14103]. Although no specific clinical drugs currently target AUF1, it is an active area of research for small molecule inhibitors and antisense therapies aimed at correcting mRNA dysregulation in cancer and chronic inflammation [PMID: 25448242].
AUF1 acts by binding to AU-rich elements (AREs) in the 3' untranslated regions of target mRNAs, where it recruits the exosome complex and other ribonucleases to facilitate rapid mRNA degradation [UniProt: Q14103]. Depending on the specific isoform (p37, p40, p42, or p45) and the cellular environment, it can also stabilize certain transcripts or modulate their translation, thereby controlling the expression of proteins involved in inflammation, cell cycle, and apoptosis [PMID: 23533556, PMID: 11500481].
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on AU-rich element RNA-binding protein 1 (AUF1) (AUF1).